Status and phase
Conditions
Treatments
About
Full description
Patients with advanced (stage IV, and Stage IIIB with effusion) non-small cell lung cancer with non-squamous histology, good performance status, and adequate organ function are eligible. Patients with brain metastases, squamous histology, or hemoptysis are excluded. All patients must give informed consent. Schema gemcitabine 1250 mg/M2 IV day 1,8 carboplatin AUC 5 IV day 1 bevacizumab 15 mg/kg IV day 1 repeated every 21 days for 6 cycles
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
Loading...
Central trial contact
Jaswinder Grewal, PhD; Michael J Kraut, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal